title: The nuclear receptor TR3 regulates mTORC1 signaling in lung cancer cells expressing wild-type p53.
abstract: The orphan nuclear receptor TR3 (NR41A and Nur77) is overexpressed in most lung cancer patients and is a negative prognostic factor for patient survival. The function of TR3 was investigated in non-small-cell lung cancer A549 and H460 cells, and knockdown of TR3 by RNA interference (siTR3) inhibited cancer cell growth and induced apoptosis. The prosurvival activity of TR3 was due, in part, to formation of a p300/TR3/ specificity protein 1 complex bound to GC-rich promoter regions of survivin and other Sp-regulated genes (mechanism 1). However, in p53 wild-type A549 and H460 cells, siTR3 inhibited the mTORC1 pathway, and this was due to activation of p53 and induction of the p53-responsive gene sestrin 2, which subsequently activated the mTORC1 inhibitor AMP-activated protein kinase α (AMPKα) (mechanism 2). This demonstrates that the pro-oncogenic activity of TR3 in lung cancer cells was due to inhibition of p53 and activation of mTORC1. 1,1-Bis(3'-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) is a recently discovered inhibitor of TR3, which mimics the effects of siTR3. DIM-C-pPhOH inhibited growth and induced apoptosis in lung cancer cells and lung tumors in murine orthotopic and metastatic models, and this was accompanied by decreased expression of survivin and inhibition of mTORC1 signaling, demonstrating that inactivators of TR3 represent a novel class of mTORC1 inhibitors.
authors.affiliation: Institute of Bioscience and Technology, Texas A&M Health Science Center, Houston, TX 77843-4466, USA.
authors.forename: S-O
authors.initials: SO
authors.lastname: Lee
authors.forename: T
authors.initials: T
authors.lastname: Andey
authors.forename: U-H
authors.initials: UH
authors.lastname: Jin
authors.forename: K
authors.initials: K
authors.lastname: Kim
authors.forename: M
authors.initials: M
authors.lastname: Singh
authors.forename: M
authors.initials: M
authors.lastname: Sachdeva
authors.forename: S
authors.initials: S
authors.lastname: Safe
mesh_terms: D055372:AMP-Activated Protein Kinases / Q000378:metabolism; D000368:Aged; D000818:Animals; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004789:Enzyme Activation / Q000187:drug effects; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D055785:Gene Knockdown Techniques; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D008175:Lung Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D008297:Male; D000076222:Mechanistic Target of Rapamycin Complex 1; D051379:Mice; D008875:Middle Aged; D046912:Multiprotein Complexes; D009687:Nuclear Proteins / Q000378:metabolism; D057105:Nuclear Receptor Subfamily 4, Group A, Member 1 / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D010636:Phenols / Q000494:pharmacology; D011379:Prognosis; D011506:Proteins / Q000378:metabolism*; D034622:RNA Interference; D015398:Signal Transduction / Q000187:drug effects; D058570:TOR Serine-Threonine Kinases; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*; D000084622:Sestrins
chemical_list: D055372:AMP-Activated Protein Kinases; D007211:Indoles; D000076222:Mechanistic Target of Rapamycin Complex 1; D046912:Multiprotein Complexes; D009687:Nuclear Proteins; D057105:Nuclear Receptor Subfamily 4, Group A, Member 1; D010636:Phenols; D011506:Proteins; D058570:TOR Serine-Threonine Kinases; D016159:Tumor Suppressor Protein p53; C552530:1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane; C465398:SESN2 protein, human; D000084622:Sestrins
references.citation: Mol Cell Biol. 2003 Dec;23(23):8651-67
references.pmid: 14612408
references.citation: Cell Death Differ. 2000 Mar;7(3):262-71
references.pmid: 10745271
references.citation: Science. 2010 Mar 5;327(5970):1223-8
references.pmid: 20203043
references.citation: Mol Pharmacol. 2010 Mar;77(3):396-404
references.pmid: 20023005
references.citation: Genes Dev. 2004 Aug 15;18(16):1926-45
references.pmid: 15314020
references.citation: EMBO J. 2006 Dec 13;25(24):5703-15
references.pmid: 17139261
references.citation: Cell Res. 2007 Aug;17(8):666-81
references.pmid: 17680028
references.citation: Cancer Cell. 2007 Jul;12(1):9-22
references.pmid: 17613433
references.citation: Hepatology. 2009 Jul;50(1):122-9
references.pmid: 19441106
references.citation: Cell. 2008 Aug 8;134(3):451-60
references.pmid: 18692468
references.citation: Histol Histopathol. 2006 May;21(5):533-40
references.pmid: 16493583
references.citation: J Exp Med. 2006 Mar 20;203(3):719-29
references.pmid: 16520388
references.citation: Expert Opin Ther Targets. 2007 Jan;11(1):69-79
references.pmid: 17150035
references.citation: Cancer Res. 2004 Nov 15;64(22):8208-12
references.pmid: 15548686
references.citation: Nat Rev Drug Discov. 2004 Nov;3(11):950-64
references.pmid: 15520817
references.citation: Neuron. 1988 May;1(3):183-8
references.pmid: 3272167
references.citation: Cancer Cell. 2008 Oct 7;14(4):285-98
references.pmid: 18835031
references.citation: Nature. 2006 May 25;441(7092):424-30
references.pmid: 16724053
references.citation: J Biol Chem. 2005 Jul 1;280(26):24903-14
references.pmid: 15871945
references.citation: Science. 2000 Aug 18;289(5482):1159-64
references.pmid: 10947977
references.citation: Nucl Recept Signal. 2006;4:e002
references.pmid: 16604165
references.citation: FASEB J. 2011 Jan;25(1):192-205
references.pmid: 20847229
references.citation: Cancer Res. 2010 May 1;70(9):3628-37
references.pmid: 20388790
references.citation: Mol Endocrinol. 2009 Jun;23(6):740-6
references.pmid: 19423650
references.citation: Cancer Res. 2007 Jan 15;67(2):674-83
references.pmid: 17234778
references.citation: Nat Chem Biol. 2008 Sep;4(9):548-56
references.pmid: 18690216
references.citation: Cancer Cell. 2010 Jul 13;18(1):39-51
references.pmid: 20609351
references.citation: Cell. 2004 Feb 20;116(4):527-40
references.pmid: 14980220
references.citation: Mol Cancer Res. 2009 Jul;7(7):1169-78
references.pmid: 19584258
references.citation: Mol Endocrinol. 2010 Oct;24(10):1891-903
references.pmid: 20392876
references.citation: Nat Rev Cancer. 2004 May;4(5):335-48
references.pmid: 15122205
references.citation: Gut. 2010 Oct;59(10):1316-30
references.pmid: 20732914
references.citation: Cancer Res. 2010 Sep 1;70(17):6824-36
references.pmid: 20660371
references.citation: Gut. 2011 Apr;60(4):534-43
references.pmid: 21068133
references.citation: Cancer Lett. 1995 Sep 4;96(1):117-22
references.pmid: 7553599